drugset / Trial / NCT01000051

Eltrombopag for Post Transplant Thrombocytopenia

NCT01000051

RandomizedSingle-groupTriple-blindTreatment

Summary

The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.

Timeline

Start
2010-02-17
Primary completion
2018-04-04
Completion
2018-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 25 mg Oral
Subject Eltrombopag Small molecule 50 mg Oral

Indications